特瑞普利单抗、卡培他滨与放疗三联方案治疗中晚期鼻咽癌的临床价值探讨  

Exploration of the Clinical Value of the Triple Therapy of Trastuzumab, Capecitabine, and Radiotherapy in the Treatment of Advanced Nasopharyngeal Carcinoma

作　　者：陈立强 韦晓谋 

机构地区：[1]柳州市工人医院科研科,广西 柳州

出　　处：《临床医学进展》2024年第12期817-822,共6页Advances in Clinical Medicine

摘　　要：目的:分析特瑞普利单抗、卡培他滨与放疗三联方案治疗中晚期鼻咽癌的效果。方法:入选样本是60例中晚期鼻咽癌患者,信封法分成两组,各30例,普通组采取卡培他滨与放疗方案,调查组采取特瑞普利单抗、卡培他滨与放疗方案,于2023年1月~2024年4月期间调查,分析不同治疗方案下的疗效、患者肿瘤标志物水平差异、免疫功能差异,观察其不良反应及远期疗效。结果:治疗有效数据相比,调查组 > 普通组,即93.33% (28例) VS 73.33% (22例),P 0.05),治疗后调查组水平均 0.05,治疗后调查组均优于普通组,P 0.05,但调查组复发率 Objective: To analyze the efficacy of the triple therapy of trastuzumab, capecitabine, and radiotherapy in the treatment of advanced nasopharyngeal carcinoma. Method: The selected sample consisted of 60 patients with advanced nasopharyngeal carcinoma. They were divided into two groups using the envelope method, with 30 patients in each group. The control group received capecitabine and radiation therapy, while the investigation group received trastuzumab, capecitabine, and radiation therapy. The study was conducted from January 2023 to April 2024 to analyze the efficacy, differences in patient tumor marker levels, and differences in immune function under different treatment regimens, and to observe their adverse reactions and long-term efficacy. Results: Compared with the control group, the effective treatment data was higher in the survey group, with 93.33% (28 cases) vs 73.33% (22 cases), P 0.05). After treatment, the average water level of the investigation group was lower than that of the ordinary group, P 0.05. After treatment, the investigation group was better than the ordinary group, P 0.05, but the recurrence rate of the survey group is lower than that of the general group, P < 0.05. Conclusion: The triple therapy of trastuzumab, capecitabine, and radiotherapy has a definite therapeutic effect on advanced nasopharyngeal carcinoma, reduces tumor marker lev

关 键 词：特瑞普利单抗 卡培他滨 放疗 中晚期鼻咽癌 有效率 肿瘤标志物 预后 

分 类 号：R73[医药卫生—肿瘤]